Wells Fargo’s Summit Therapeutics SMMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.04M | Buy |
208,413
+88,112
| +73% | +$1.56M | ﹤0.01% | 3263 |
|
|
2026
Q1 | $2.28M | Sell |
120,301
-10,585
| -8% | -$171K | ﹤0.01% | 3178 |
|
|
2025
Q4 | $2.29M | Sell |
130,886
-61,990
| -32% | -$1.17M | ﹤0.01% | 3332 |
|
|
2025
Q3 | $3.98M | Sell |
192,876
-41,844
| -18% | -$1.01M | ﹤0.01% | 2750 |
|
|
2025
Q2 | $4.99M | Buy |
234,720
+108,450
| +86% | +$2.47M | ﹤0.01% | 2472 |
|
|
2025
Q1 | $2.44M | Buy |
126,270
+31,005
| +33% | +$622K | ﹤0.01% | 3013 |
|
|
2024
Q4 | $1.7M | Buy |
95,265
+41,890
| +78% | +$812K | ﹤0.01% | 3323 |
|
|
2024
Q3 | $1.17M | Buy |
53,375
+19,293
| +57% | +$270K | ﹤0.01% | 3441 |
|
|
2024
Q2 | $266K | Sell |
34,082
-5,655
| -14% | -$30.5K | ﹤0.01% | 4323 |
|
|
2024
Q1 | $165K | Buy |
39,737
+4,636
| +13% | +$18.4K | ﹤0.01% | 4589 |
|
|
2023
Q4 | $91.6K | Buy |
35,101
+6,844
| +24% | +$14.1K | ﹤0.01% | 4959 |
|
|
2023
Q3 | $52.8K | Sell |
28,257
-25,021
| -47% | -$47.7K | ﹤0.01% | 5149 |
|
|
2023
Q2 | $134K | Buy |
53,278
+48,049
| +919% | +$87.7K | ﹤0.01% | 4838 |
|
|
2023
Q1 | $9.15K | Sell |
5,229
-477
| -8% | -$1.3K | ﹤0.01% | 5887 |
|
|
2022
Q4 | $24.3K | Sell |
5,706
-15,394
| -73% | -$28K | ﹤0.01% | 5183 |
|
|
2022
Q3 | $25K | Buy |
21,100
+200
| +1% | +$226 | ﹤0.01% | 5294 |
|
|
2022
Q2 | $21K | Sell |
20,900
-22,686
| -52% | -$31.8K | ﹤0.01% | 5429 |
|
|
2022
Q1 | $107K | Sell |
43,586
-40,900
| -48% | -$103K | ﹤0.01% | 5294 |
|
|
2021
Q4 | $227K | Sell |
84,486
-92,574
| -52% | -$445K | ﹤0.01% | 5198 |
|
|
2021
Q3 | $886K | Buy |
177,060
+123,895
| +233% | +$889K | ﹤0.01% | 4326 |
|
|
2021
Q2 | $397K | Buy |
53,165
+1,765
| +3% | +$11.6K | ﹤0.01% | 4733 |
|
|
2021
Q1 | $302K | Buy |
51,400
+6,400
| +14% | +$41.3K | ﹤0.01% | 4969 |
|
|
2020
Q4 | $212K | Buy |
45,000
+10,000
| +29% | +$42.3K | ﹤0.01% | 5058 |
|
|
2020
Q3 | $120K | Buy |
35,000
+5,170
| +17% | +$17.9K | ﹤0.01% | 5186 |
|
|
2020
Q2 | $89K | Buy |
29,830
+27,830
| +1,392% | +$96K | ﹤0.01% | 5274 |
|
|
2020
Q1 | $5K | Buy |
+2,000
| New | +$3.44K | ﹤0.01% | 5862 |
|
|
2019
Q4 | – | Sell |
-2,000
| Closed | -$4K | – | 6699 |
|
|
2019
Q3 | $4K | Buy |
+2,000
| New | +$2.71K | ﹤0.01% | 6115 |
|
|
2017
Q2 | – | Sell |
-1,200
| Closed | -$16K | – | 6426 |
|
|
2017
Q1 | $16K | Hold |
1,200
| – | – | ﹤0.01% | 5759 |
|
|
2016
Q4 | $10K | Hold |
1,200
| – | – | ﹤0.01% | 5810 |
|
|
2016
Q3 | $11K | Sell |
1,200
-200
| -14% | -$1.44K | ﹤0.01% | 5738 |
|
|
2016
Q2 | $11K | Sell |
1,400
-1,100
| -44% | -$8.95K | ﹤0.01% | 5642 |
|
|
2016
Q1 | $17K | Hold |
2,500
| – | – | ﹤0.01% | 5554 |
|
|
2015
Q4 | $29K | Hold |
2,500
| – | – | ﹤0.01% | 5478 |
|
|
2015
Q3 | $26K | Buy |
+2,500
| New | +$29.9K | ﹤0.01% | 5462 |
|
Other funds holding SMMT
BBA
Wells Fargo's SMMT Position: Q2 2026 in Review
Wells Fargo increased its Summit Therapeutics (SMMT) stake by 73% in Q2 2026, buying an estimated $1.56M and bringing the position to 208,413 shares worth $3.04M. The position accounts for ﹤0.01% of the portfolio, ranked #3263.
Wells Fargo first reported a position in SMMT in Q3 2015 and has held it in 34 quarters since. The position peaked at $4.99M in Q2 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.
- Wells Fargo held 208,413 shares of Summit Therapeutics worth $3.04M as of Q2 2026.
- Wells Fargo bought 88,112 Summit Therapeutics shares in Q2 2026, an estimated $1.56M.
- Summit Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #3263 holding.
- Wells Fargo first reported a position in Summit Therapeutics in Q3 2015 and has held it in 34 quarters since.
- Wells Fargo's Summit Therapeutics position peaked at $4.99M in Q2 2025.
- 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.
Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.